Cargando…
Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
BACKGROUND: Mucopolysaccharidosis type I-Hurler syndrome (MPSI-H) is a lysosomal storage disease characterized by severe physical symptoms and cognitive decline. Early treatment with hematopoietic cell transplant (HSCT) is critical to the survival of these patients. While survival rates and short-te...
Autores principales: | Guffon, N., Pettazzoni, M., Pangaud, N., Garin, C., Lina-Granade, G., Plault, C., Mottolese, C., Froissart, R., Fouilhoux, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847591/ https://www.ncbi.nlm.nih.gov/pubmed/33517895 http://dx.doi.org/10.1186/s13023-020-01644-w |
Ejemplares similares
-
Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation
por: Polgreen, Lynda E., et al.
Publicado: (2019) -
Enzyme replacement therapy in Hurler syndrome after failure of hematopoietic transplant
por: Arranz, Leonor, et al.
Publicado: (2015) -
A rare late progression form of Sly syndrome mucopolysaccharidosis
por: Guffon, Nathalie, et al.
Publicado: (2019) -
COVID-19 and HSCT (Hematopoietic stem cell transplant)
por: Strasfeld, Lynne
Publicado: (2022) -
Orthopaedic management of Hurler’s disease after hematopoietic stem cell transplantation: a systematic review
por: van der Linden, Marleen H., et al.
Publicado: (2011)